Rahsaan Thompson's most recent trade in Zevra Therapeutics Inc was a trade of 75,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 37,500 | 37,500 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 11,333 | 22,667 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 11,333 | 53,999 (0%) | 0% | - | Common Stock | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Sale of securities on an exchange or to another person at price $ 8.83 per share. | 29 Jan 2026 | 4,080 | 49,919 (0%) | 0% | 8.8 | 36,010 | Common Stock |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Sale of securities on an exchange or to another person at price $ 9.21 per share. | 26 Jun 2025 | 24,000 | 42,666 (0%) | 0% | 9.2 | 221,004 | Common Stock |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2025 | 66,666 | 133,334 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2025 | 66,666 | 66,666 (0%) | 0% | - | Common Stock | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 68,000 | 68,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 34,000 | 34,000 | - | - | Restricted Stock Unit | |
| Zevra Therapeutics Inc | Rahsaan W. Thompson | Chief Legal & Compliance, Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 200,000 | 200,000 | - | - | Restricted Stock Unit | |
| Lyell Immunopharma Inc | Rahsaan Thompson | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 245,000 | 245,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Rahsaan Thompson | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2022 | 715,000 | 715,000 | - | - | Option (right to buy) | |
| Gritstone Bio Inc | Rahsaan Thompson | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 115,440 | 115,440 | - | - | Stock Option (Right to Buy) | |
| Gritstone Bio Inc | Rahsaan Thompson | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 19,240 | 58,698 (0%) | 0% | 0 | Common Stock |